Dostarlimab

Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively[1].

Product Specifications

CAS Number

[2022215-59-2]

Product Name Alternative

TSR-042; ANB-011; WBP-285

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dostarlimab.html

Purity

98.92

Solubility

H2O

Smiles

[Dostarlimab]

Molecular Weight

(144.18 kDa)

References & Citations

[1]Kumar S, et al. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. MAbs. 2021 Jan-Dec;13 (1) :1954136.